Figure 2
![Figure 2. Flow cytometry figure comparing B-cell populations in a healthy volunteer (Ctrl), and in a patient with HCV-MC vasculitis before (MC pre-Rx) and after (at month +1 [MC post-Rx M1] and at month +12 [MC post-Rx M12]) rituximab.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/111/11/10.1182_blood-2007-11-122713/6/zh80090818790002.jpeg?Expires=1724157749&Signature=k6~NPX67TjDfGrU7-AyXvLhD4VPoVQB9NuM7lJbI6ymTvFporACLflHTb9SrETQqfWeGpKmTYJnyGyLb41eQhddDkA3JdjjShqV5C2fM4nNMskLknI9zz3k3RkgqWJgDlNP92QdY6zh07vKZJBNoq36a2vqFOeRUSX7omsya1EexiDaR8WoxPkydHDJm5ZZ20TgApGyGnPB08bXqunKo3qgff~23Z6L-lv~YdJ6vC3QPWu5Ssqki6~RTzNepqVoH8uPZuW~T9ZbYwYjRLRVao8bm0E2V8qNHA0ntSVaE-iypW8jcah4kDcIELJx5f-EP3Trsi-S~JmMjwOlECz8Tow__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Flow cytometry figure comparing B-cell populations in a healthy volunteer (Ctrl), and in a patient with HCV-MC vasculitis before (MC pre-Rx) and after (at month +1 [MC post-Rx M1] and at month +12 [MC post-Rx M12]) rituximab.
Flow cytometry figure comparing B-cell populations in a healthy volunteer (Ctrl), and in a patient with HCV-MC vasculitis before (MC pre-Rx) and after (at month +1 [MC post-Rx M1] and at month +12 [MC post-Rx M12]) rituximab.
